|
Patient number
|
Age (years)
|
ANCA type
|
Disease duration (months)
|
Disease activity at time of sampling
|
BVAS
|
CRP (mg/L)
|
|---|
|
1
|
55
|
PR3
|
0
|
A, ENT, K, L
|
25
|
292
|
|
2
|
37
|
PR3
|
44
|
A, ENT
|
5
|
20
|
|
3
|
55
|
PR3
|
57
|
A, K, L
|
15
|
247
|
|
4
|
58
|
MPO
|
120
|
A, L
|
7
|
23
|
|
5
|
49
|
PR3
|
190
|
A, ENT, L
|
10
|
46
|
|
6
|
57
|
PR3
|
259
|
Ey, ENT
|
6
|
< 5
|
|
7
|
56
|
PR3
|
191
|
Ey
|
6
|
< 5
|
|
8
|
82
|
MPO
|
0
|
L
|
4
|
44
|
|
9
|
53
|
PR3
|
0
|
A, ENT, K, L
|
17
|
160
|
|
10
|
74
|
PR3
|
0
|
K
|
10
|
NA
|
|
11
|
69
|
PR3
|
9
|
ENT, K
|
14
|
211
|
|
12
|
41
|
MPO
|
0
|
A, ENT, K, S
|
17
|
44
|
|
13
|
58
|
MPO
|
0
|
ENT, K, S
|
14
|
116
|
|
14
|
70
|
MPO
|
0
|
A, ENT, K, L
|
19
|
188
|
|
15
|
53
|
PR3
|
15
|
Ey, K
|
12
|
12
|
|
16
|
24
|
PR3
|
9
|
A, Ey
|
3
|
16
|
|
17
|
40
|
MPO
|
33
|
ENT
|
6
|
< 5
|
|
18
|
41
|
MPO
|
284
|
K, L
|
12
|
< 5
|
- None of the patients received induction therapy at the time of sampling. PR3/MPO, proteinase-3/myeloperoxidase; this reflects anti-neutrophil-cytoplasmic antibodies specificity (ANCA) at the time of diagnosis. Organ involvement of patients with active disease at the time of sampling is depicted. A, arthritis (joints); BVAS, Birmingham Vasculitis Activity Score; CRP, C-reactive protein; ENT, ear-nose-throat; Ey, ophthalmologic manifestation of disease; K, kidney; L, lung; S, skin.
